Background and FDAs Announcement FDA's April 1, 2026, update to its compounding policy page follows more than 18 months of regulatory activity surrounding the compounding of GLP-1 medications, primarily semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound)
They dont have diabetes, but believe tirzepatide could help
From there, its possible to store the solution between 2 and 8C for multi-dose experiments up to 30-60 days
Retatrutide 30mg is sold strictly for controlled, non-clinical laboratory research
Relatively common side effects Internal bleeding or itching at the injection site, diarrhea, constipation, headache Severe side effects hypoglycemia, pancreatitis, bowel obstruction, palpitations *Although GLP-1 alone rarely causes hypoglycemia, it has been reported that combined use with insulin or oral hypoglycemic agents can cause severe hypoglycemia